Cholesterol-lowering effect of platycodin D in hypercholesterolemic ICR mice

Area of Science:

• Biochemistry
• Pharmacology
• Nutraceuticals

Background:

• Hypercholesterolemia is a significant risk factor for cardiovascular diseases.
• Natural compounds are increasingly explored for their cholesterol-lowering potential.
• Platycodin D, a saponin from Platycodon grandiflorus, warrants investigation for its effects on lipid metabolism.

Purpose of the Study:

• To investigate the in vivo hypocholesterolemic effects of platycodin D in a mouse model.
• To explore the in vitro mechanisms underlying platycodin D's cholesterol-lowering properties.

Main Methods:

• Oral administration of platycodin D (15, 30, 50 mg/kg) to male ICR mice for 8 weeks.
• Measurement of body weight, food intake, and serum, liver, and fecal lipid profiles (triglyceride, cholesterol).
• In vitro assays including antioxidant activity, inhibition of hACAT and Lp-PLA(2), farnesoid X receptor regulation, and cholesterol complex formation.

Main Results:

• Platycodin D significantly reduced body weight and food intake in a dose-dependent manner.
• Serum and liver triglyceride and cholesterol levels were decreased, while fecal lipid excretion increased.
• In vitro studies indicated platycodin D inhibits hACAT, antagonizes the farnesoid X receptor, and forms insoluble complexes with cholesterol.

Conclusions:

• Platycodin D demonstrates significant in vivo hypocholesterolemic and anti-atherogenic effects.
• Mechanisms include hACAT inhibition, farnesoid X receptor antagonism, and direct cholesterol complexation.
• Platycodin D shows promise as a novel therapeutic candidate for managing hypercholesterolemia.